Nur auf Docsity: Lade Breast DisordersBreast Disorders und mehr Übungen als PDF für Corporate Finance herunter!
Breast
Disorders
The following is a comprehensive, in-depth guide to breast disorders, integrating advanced hormonal evaluation, a thorough diagnostic workup, and several illustrative case studies.
Table of Contents
- Advanced Hormonal Evaluation in Breast Disorders
- Comprehensive Diagnostic Workup
- Common Breast Disorders: Classification & Overview
- Detailed Case Studies
- Exam Questions (with Answers)
1. Advanced Hormonal Evaluation in Breast Disorders
Breast tissue is exquisitely sensitive to the complex interplay of reproductive and metabolic hormones. A deep understanding of these hormonal mechanisms is crucial for accurate diagnosis and management.
1.1. Core Hormonal Panel
A comprehensive evaluation begins with the following core panel, especially when investigating conditions like galactorrhea, severe cyclical mastalgia, or endocrine-related breast growth.
HormoneBiological Role in BreastClinical Indication for Testing
Prolactin (PRL)Primary stimulus for lactogenesis (milk production). Hyperprolactinemia causes galactorrhea and may influence benign breast hyperplasia.Galactorrhea, infertility, menstrual irregularities, or suspicion of a prolactinoma.
Estradiol (E2)Potent stimulator of ductal growth and proliferation. Elevated levels are linked to increased breast cancer risk and can worsen mastalgia.Cyclic mastalgia, fibrocystic changes, evaluating hormonal milieu in breast cancer risk.
Progesterone (P4)Counteracts estrogen's proliferative effects on the breast, promoting differentiation and having an anti-proliferative effect.Works with estradiol to assess the full hormonal balance.
Luteinizing Hormone (LH) &
Follicle-Stimulating Hormone (FSH)Gonadotropins that control ovarian production of estradiol and progesterone. Key for assessing menopausal status.
Perimenopausal or menopausal women; evaluating ovulatory function in those with cyclical breast pain. |
1.2. When to Order Advanced Hormonal Testing
Advanced testing is not required for every patient. It is indicated in specific clinical scenarios:
- Galactorrhea: Confirm hyperprolactinemia. Normal levels require repeat testing, assessment for macroprolactin, and thyroid function tests (TFTs) to rule out hypothyroidism as a cause.
- Severe Cyclical Mastalgia: To assess the estrogen-progesterone balance, especially if pain is refractory to first-line conservative measures.
- Gynecomastia in Males: Evaluate the androgen-estrogen balance with total testosterone, estradiol, LH, and PRL.
- Suspected Prolactinoma: Markedly elevated PRL (>200 μg/L) in the absence of interfering medications is a strong indicator and warrants MRI.
| Ultrasound (US) | Differentiating solid from cystic masses. First-line in women <30. Guided biopsies. | Provides real-time evaluation; defines internal echotexture, margins, and vascularity. | | Magnetic Resonance Imaging (MRI) | High-risk screening, problem-solving, evaluating extent of disease. | High sensitivity; uses contrast to assess lesion vascularity (kinetics). |
2.3. Pathological Tissue Sampling
ProcedureIndicationsDetails
Fine-Needle Aspiration (FNA)Simple cysts, palpable masses. Provides cytology (cells), not histology (tissue architecture).Cannot definitively diagnose invasive carcinoma vs. in situ.
Core Needle Biopsy (CNB)Solid masses, microcalcifications, or BI-RADS 4/5 lesions. Gold standard.Provides a histologic core, allowing definitive diagnosis and biomarker testing (ER, PR, HER2).
Vacuum-Assisted Biopsy (VAB)Complete removal of small, benign-appearing lesions (e.g., papillomas, radial scars).Minimally invasive alternative to surgical excision for certain lesions.
2.4. Key Laboratory Tests
Beyond the hormonal panel, the following labs are part of a complete workup:
- Complete Blood Count (CBC): To assess for anemia (secondary to chronic disease or malignancy) or leukocytosis (infectious/inflammatory process).
- Comprehensive Metabolic Panel (CMP): To rule out liver, kidney, or metabolic causes contributing to hormonal imbalances or mastalgia.
- Thyroid Function Tests (TFTs): Hypothyroidism is a known cause of hyperprolactinemia and can lead to galactorrhea and cyclical breast pain.
- β-hCG: Mandatory in any reproductive-age woman with galactorrhea, mastalgia, or a breast mass, as pregnancy dramatically alters the hormonal milieu.
3. Common Breast Disorders: Classification & Overview
DisorderKey PresentationHormonal/Age Link
FibroadenomaSolitary, mobile, "breast mouse" lump; most common in women <30. Hormonally responsive; may enlarge during pregnancy or with hormone therapy.
Fibrocystic ChangesCyclical breast pain, lumpiness, and nodularity, worsening premenstrually. Driven by fluctuating estrogen and progesterone levels.
Mastalgia70% of women experience. Cyclical (hormonal) vs. non-cyclical vs. extramammary. Cyclical type is strongly linked to hormonal variations of the menstrual cycle.
GalactorrheaMilky or serous nipple discharge unrelated to pregnancy/breastfeeding.Caused by hyperprolactinemia; can be idiopathic or due to microprolactinoma.
Granulomatous MastitisPainful, unilateral inflammatory mass mimicking breast cancer. Often in parous women.Associations with pregnancy, lactation, oral contraceptives, and hyperprolactinemia.
GynecomastiaBenign enlargement of male breast glandular tissue.Due to estrogen-androgen imbalance; physiologic (neonatal, pubertal, aging) or pathologic.
Breast CarcinomaPainless, hard, fixed mass; skin changes (peau d'orange) or nipple retraction. Estrogen receptor-positive cancers are driven by hormonal milieu; risk increases with age.
4. Detailed Case Studies
Case Study 1: Recurrent Bilateral Giant Fibroadenomas with Hormonal and Genetic Findings
A 23-year-old woman with a history of multiple fibroadenoma excisions presented with progressively enlarging bilateral breast masses and marked breast deformity. Imaging revealed multiple well- circumscribed lesions, the largest measuring 7.5 cm. She had no personal or family history of breast cancer. Laboratory evaluation revealed a serum prolactin of 52.5 ng/mL (reference range: 5.18–26. ng/mL) with normal estradiol and progesterone. She underwent bilateral excision with reduction mammoplasty. Histology confirmed fibroadenomas with diffuse estrogen receptor positivity (>90%). Next-generation sequencing identified a somatic PIK3CA p.G106V mutation. Key Learning Points:
ultrasound confirmed glandular tissue without focal masses. Given the temporal relationship and lack of other causes, his gynecomastia was attributed to spironolactone use. The medication was discontinued and replaced with eplerenone. At a 4-month follow-up, his breast tenderness had resolved and the tissue had partially regressed. Key Learning Points:
- Spironolactone is a common cause of medication-induced gynecomastia, due to its anti-androgen effects.
- Gynecomastia is a manifestation of estrogen-androgen imbalance and can be physiologic, drug- induced, or due to underlying disease.
- The basic diagnostic workup includes a thorough history, physical exam, breast and testicular sonography, and a core hormonal panel (tT, E2, LH, hCG, PRL).
- Removing the offending agent often leads to resolution, especially if gynecomastia has been present for less than 12 months.
Case Study 4: Galactorrhea and Hyperprolactinemia in a Premenopausal Woman
A 29-year-old woman presented with bilateral milky nipple discharge for 6 months, not associated with pregnancy or breastfeeding. She also reported irregular menses (oligomenorrhea) and occasional headaches. Her only medication was an oral contraceptive. Prolactin level was 95 ng/mL (normal < μg/L). A pregnancy test was negative. MRI of the pituitary gland revealed a 6-mm microadenoma, confirming a prolactinoma. Cabergoline was initiated at 0.25 mg twice weekly. Within 8 weeks, galactorrhea resolved completely and menses normalized. Prolactin level returned to normal after 3 months of therapy. Repeat MRI at 12 months showed reduction in the size of the microadenoma. Key Learning Points:
- Galactorrhea is the classic presentation of a prolactinoma but can also be caused by medications or hypothyroidism.
- Normal prolactin levels do not entirely rule out the diagnosis; levels correlate with tumor size (100– 200 μg/L for <1 cm to >10,000 μg/L for >3 cm).
- Dopamine agonists (cabergoline) are first-line therapy, effectively normalizing prolactin levels, reducing tumor size, and resolving galactorrhea.
- MRI of the pituitary is indicated when prolactin remains elevated after excluding secondary causes.
5. Exam Questions (with Answers)
Question 1
A 28-year-old woman presents with bilateral milky nipple discharge for 4 months. She has irregular periods and is not pregnant. Which initial laboratory test is most appropriate?
- A) Serum estradiol
- B) Serum progesterone
- C) Serum prolactin
- D) Thyroid-stimulating hormone (TSH) Answer: C Explanation: Galactorrhea is the production of breast milk in a non-lactating individual. The primary stimulus for lactation is prolactin. Therefore, the initial test of choice is a serum prolactin level. An elevated prolactin level (hyperprolactinemia) will guide the subsequent diagnostic evaluation, which may include TSH, pregnancy test, and potentially pituitary imaging.
Question 2
An MRI of the pituitary is indicated for a patient with galactorrhea only in which of the following scenarios?
- A) Normal prolactin level
- B) Mild prolactin elevation on a single test
- C) Persistent prolactin elevation after excluding secondary causes like hypothyroidism or macroprolactin
- D) All patients with galactorrhea regardless of prolactin level
- B) The differential diagnosis must include granulomatous mastitis (GM), which is a common condition in this setting.
- C) Given the strong association with malignancy, an urgent core needle biopsy is mandatory.
- D) A trial of oral antibiotics for 10 days is the appropriate first step. Answer: B Explanation: The presentation of a painful, unilateral breast mass in a postpartum or lactating woman is characteristic of granulomatous mastitis. While the patient should be evaluated, the initial differential should include infectious mastitis, a breast abscess, and GM. Option A is incorrect; fibroadenomas are typically painless and not commonly associated with the postpartum period. Option C is not mandatory without further evaluation; malignancy is less likely in this demographic and presentation. Option D is incorrect; while antibiotics may be trialed for infectious mastitis, GM is a non- infectious inflammatory condition and will not respond.
Question 5
A 52-year-old postmenopausal woman presents with new-onset, left-sided non-cyclical breast pain localized to the upper outer quadrant. She has a history of hypertension and osteoarthritis. Her breast exam is unremarkable with no palpable masses, skin changes, or nipple discharge. What is the most appropriate next step?
- A) Reassurance and observation.
- B) Diagnostic mammogram and ultrasound.
- C) Trial of hormone replacement therapy (HRT).
- D) Topical NSAIDs and a better-fitting bra. Answer: B Explanation: Any new, persistent, focal breast pain in a postmenopausal woman should be evaluated with diagnostic imaging to rule out an underlying malignancy, even in the absence of a palpable mass. Option D is a management strategy, not the next diagnostic step. Reassurance and observation (option A) are insufficient. HRT (option C) is not a first-line treatment for de novo breast pain and carries risks that should be carefully considered.
This comprehensive overview provides a structured, evidence-based approach to breast disorders. Each section is designed to stand alone for easy reference and can be copied for educational or clinical use.
